Short Interest in Haleon plc (NYSE:HLN) Increases By 5.8%

Haleon plc (NYSE:HLN) was the target of a large growth in short interest in November. As of November 30th, there was short interest totalling 12,420,000 shares, a growth of 5.8% from the November 15th total of 11,740,000 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 6,260,000 shares, the short-interest ratio is currently 2.0 days.

Haleon Price Performance

HLN opened at $9.93 on Wednesday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon has a 12-month low of $7.89 and a 12-month high of $10.80. The business’s fifty day simple moving average is $9.74 and its 200-day simple moving average is $9.54. The company has a market capitalization of $44.93 billion, a price-to-earnings ratio of 29.19, a PEG ratio of 2.95 and a beta of 0.28.

Hedge Funds Weigh In On Haleon

Several institutional investors have recently bought and sold shares of HLN. Fortitude Family Office LLC purchased a new position in Haleon in the third quarter worth $28,000. Toronto Dominion Bank boosted its position in shares of Haleon by 3,470.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after purchasing an additional 3,470 shares in the last quarter. Cultivar Capital Inc. purchased a new position in Haleon during the 2nd quarter worth $40,000. Prospera Private Wealth LLC acquired a new position in Haleon during the 3rd quarter valued at about $57,000. Finally, BOKF NA raised its stake in Haleon by 68.8% in the second quarter. BOKF NA now owns 6,972 shares of the company’s stock valued at $58,000 after buying an additional 2,842 shares during the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on HLN shares. UBS Group raised shares of Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. Morgan Stanley boosted their target price on Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research report on Friday, September 20th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Haleon currently has a consensus rating of “Buy” and a consensus target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.